Skip to main content

Table 1 Main characteristics of the 753 leprosy patients from UMDT/CT-BR study in PB and MB cases stratified according to the development of leprosy reaction and other manifestations

From: Can baseline ML Flow test results predict leprosy reactions? An investigation in a cohort of patients enrolled in the uniform multidrug therapy clinical trial for leprosy patients in Brazil

 

Number

Sex

(F/M)

Age

(median, range)

R&J

BI

(median,range)

BCG scar (presence of scar/total)

PB reaction-free

129

86/43

34 (9-65)

11 I/ 42TT/ 75 BT/ 1BB

0 (0-1.75)

66/129

PB with RR

13

8/5

38 (6-60)

3 TT/ 7 BT/ 3 BB

0 (0-2.6)

6/13

PB with neuritis

16

10/6

39 (11-63)

3 TT/ 12BT/1BB

0 (0-0.75)

7/16

MB reaction-free

206

91/115

43 (8-65)

115 BT/ 9 BB/ 44 BL/ 38 LL

0 (0-6)

106/206

MB with RR

153

35/118

43 (7-65)

30 BT/ 17 BB/106 BL

2.75 (0-6)

78/153

MB with ENL

48

16/32

33 (8-62)

15 BL/ 33 LL

4.5 (0.5-5.6)

23/48

MB with others CM

55

17/38

45 (11-65)

9 BT/ 3 BB/ 26 BL/ 17 LL

4 (0-6)

30/55

MB with neuritis

133

42/91

36 (10-64)

47 BT/ 7 BB/ 43 BL/ 36 LL

4 (0-5.75)

53/133

  1. PB Paucibacillary Leprosy, MB Multibacillary Leprosy, RR Reversal Reaction, ENL Erythema Nodosum Leprosum, CM clinical manifestations, n number, F female, M male, R & J Ridley & Jopling Classification, BI Bacilloscopic Index, BCG Bacillus Calmette Guérin vaccine. PB and MB leprosy cases classification was based on the number of skin lesions according to WHO operational classification system